生物制剂治疗Behcet病葡萄膜炎的研究进展

A review of advances in biologic therapy for Behcet uveitis

Behcet病葡萄膜炎(BU)是Behcet综合征常见表现之一,其预后差,致盲率高,严重降低患者生活质量。目前的治疗主要是通过抑制免疫应答来诱导和缓解炎症,既往常用的糖皮质激素联合免疫抑制剂疗法存在用药时间长、副作用大、远期预后差等不足,而生物制剂因其高效性、低毒性、远期预后好的优势逐渐成为治疗难治型BU的研究热点,为BU的治疗提供了新方向。目前用于治疗BU的生物制剂包括肿瘤坏死因子-α抑制剂、干扰素制剂、白细胞介素阻断剂和淋巴细胞靶向制剂。相信随着各项研究的深入和临床试验的进展,生物制剂在临床的逐步应用指日可待,未来有望为BU患者提供更精准有效的治疗。

Behget uveitis(BU),one of the common manifestations of Behqet syndrome,has a poor prognosis,high blinding rate,and severely impairs the quality of patients'life.The current treatment principle mainly induce and maintain inflammation remission by suppressing the immune response.The glucocorticoid combined with immunosuppressive therapy for the treatment of BU has disadvantages such as long medication time,severe adverse effects,and poor long-term prognosis,whereas biologies have gradually attracted attention about the treatment of BU because of their high efficacy,low toxicity,and good long-term prognosis.The biologies used to treat BU include tumor necrosis factor-a inhibitors,interferon-α,interleukin blockers,and lymphocyte targeting preparations.It is believed that with the progress of various studies and clinical trials,the stepwise application of biologies is promising,and it is hopeful to provide more accurate and effective treatment for patients with BU in the future.